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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is associated with liver-
related morbidity, including progression to nonalcoholic steato-
hepatitis (NASH), advanced fibrosis, and hepatocellular carcinoma 
(HCC). NAFLD is the fastest growing cause of HCC in liver trans-
plant candidates,1 and it is projected that NAFLD is becoming the 
leading cause of liver transplantation.2 NAFLD can be coexistent 
Beneficial effect of anti-diabetic drugs for nonalcoholic 
fatty liver disease
Kyung-Soo Kim1 and Byung-Wan Lee2 
1Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of 
Medicine, Seongnam; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of 
Medicine, Seoul, Korea
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic 
diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment 
option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-
diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated 
by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-
line therapy for T2DM patients with NAFLD, based on evidence of histological improvement in patients with biopsy-
proven nonalcoholic steatohepatitis (NASH). Liraglutide, another promising alternative, is not yet recommended in 
patients with NAFLD/NASH due to limited evidence. Therefore, well-designed randomized controlled trials should be 
performed in the near future to demonstrate if and how anti-diabetic drugs can play a role in the treatment of NAFLD. (Clin 
Mol Hepatol 2020;26:430-443)
Keywords: Anti-diabetic drug; Diabetes mellitus; Metabolic diseases; Non-alcoholic fatty liver disease; Treatment
Copyright © 2020 by Korean Association for the Study of the Liver
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
431
Kyung-Soo Kim, et al. 
Anti-diabetic drugs for NAFLD
http://www.e-cmh.org https://doi.org/10.3350/cmh.2020.0137
with type 2 diabetes mellitus (T2DM), and this combination re-
sults in the undesirable consequence of cardiovascular (CV) 
events, which underscores the need for lifestyle modification in 
the management of NAFLD regardless of diabetes.3,4 NAFLD is the 
one of the most common liver disorders, affecting approximately 
20–40% of the population worldwide, with different burdens ac-
cording to age, sex, ethnicity, and diagnostic tools.5,6 The pres-
ence of diabetes is closely associated with the severity of NAFLD, 
progression to NASH, advanced fibrosis, cirrhosis, and even HCC,7-9 
independently of liver enzymes.10,11 Studies on South Korean pa-
tients with T2DM who underwent ultrasonography in a university 
and a private clinic-based diabetes care facility showed 63.3% 
and 72.7% prevalence of NAFLD, respectively.12,13 A recent meta-
analysis reported that the global prevalence of NAFLD and NASH 
among patients with T2DM is 55.5% and 37.3%, respectively.14 
The European Association for the Study of the Liver, the European 
Figure 1. Mechanism of action and effects of anti-diabetic drugs on glucose metabolism. DPP-4, dipeptidyl peptidase-4; GLP-1 RA, glucagon-like 
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Association for the Study of Diabetes, and the European Associa-
tion for the Study of Obesity, in their joint clinical practice guide-
lines for the management of NAFLD recommend screening for 
NAFLD in T2DM patients and vice versa.15 Although weight reduc-
tion is the cornerstone of therapy among the various treatments 
for NAFLD,16 pharmacotherapy should be administered since suffi-
cient weight reduction can be difficult to achieve and maintain. In 
subjects with T2DM and NAFLD, management with anti-diabetic 
drugs is more effective than lifestyle modification in controlling 
glucose level (Fig. 1). Moreover, lifestyle changes, together with 
anti-diabetic medications, are likely to have an additive effect on 
reducing the risk factors associated with CV diseases, decreasing 
hepatic fat accumulation, and delaying progression to NASH and 
fibrosis. Although there is no approved drug of choice for manag-
ing NAFLD, many anti-diabetic drugs have been tested in patients 
with NAFLD due to the shared epidemiological and pathophysio-
logical features between NAFLD and T2DM. The aim of this re-
view is to summarize the beneficial effects of anti-diabetic drugs 
for NAFLD.
METFORMIN
Metformin has been derived from the guanidine-rich Galega of-
ficinalis  (goat’s rue or French lilac), and is a kind of general insulin 
sensitizer.17 Although its molecular mechanisms of action are com-
plex and not completely understood, metformin has been shown 
to act via both adenosine monophosphate-activated protein ki-
nase (AMPK)-dependent and AMPK-independent mechanisms, by 
the inhibition of mitochondrial respiration but also perhaps by the 
inhibition of mitochondrial glycerophosphate dehydrogenase and 
a mechanism involving lysosomes at the molecular level (Table 1).18 
Physiologically, metformin reduces blood glucose level by domi-
nantly inhibiting hepatic glucose production via AMPK activation, 
stimulation of muscle glucose uptake, and decrease of intestinal 
glucose absorption.18 All current guidelines recommend metformin 
as the first-line agent for T2DM.19,20
Since metformin improves insulin resistance, which is the major 
pathogenesis of NAFLD, it has been widely tested in both animal 
NAFLD models and human clinical trials. In the insulin-resistant 
ob/ob mouse model with hepatic steatosis, metformin improved 
fatty liver disease and reversed the hepatomegaly, steatosis, and 
alanine aminotransferase (ALT) level by decreasing the expression 
of tumor necrosis factor-alpha (TNF-α) and TNF-inducible factors 
that promote hepatic lipid accumulation and adenosine triphos-
phate depletion21 or autophagy activation.22 In a pilot study of 
20 non-diabetic patients with NAFLD, metformin treatment for 
4 months reduced liver enzymes and improved insulin sensitivity 
and liver volume as detected by ultrasound.23 However, among 
well-designed randomized controlled trials (RCTs), the TONIC trial, 
which recruited 173 non-diabetic patients aged 8–17 years with 
biopsy-proven NAFLD and persistent increase in ALT, did not dem-
onstrate reduced ALT level and improved liver histology with met-
formin compared to placebo.24 To date, meta-analyses have 
shown that metformin could improve liver function, insulin resis-
tance, and body mass index (BMI) to some extent, but does not 
impact histological response in NAFLD patients.25-27 In this regard, 
current guidelines do not recommend metformin for treating 
NASH in adult patients.15,28 Despite the lack of known benefits to 
treat NAFLD, metformin aids in reducing CV risks related to dia-
betes. Furthermore, a meta-analysis of case-control studies found 
that metformin use was associated with a reduced risk of HCC, 
which is the final sequence of NAFLD, and it may be a relevant 
factor in preventing HCC in diabetic patients.29 Based on these 
studies, metformin could be beneficial for NAFLD patients with 
T2DM.
THIAZOLIDINEDIONES
Thiazolidinediones (TZDs) are peroxisome proliferator-activated 
receptor-γ (PPAR-γ) agonists that act as insulin sensitizers on adi-
pose tissue, muscle, and liver. TZDs improve insulin and glucose 
parameters, modulate adipose tissue distribution while decreasing 
visceral fat and increasing subcutaneous fat, and reduce lipotoxic-
ity in the liver. In addition, TZDs have demonstrated anti-inflam-
matory and antioxidant properties.
Pioglitazone
Pioglitazone was widely evaluated for the treatment of NAFLD. 
Many RCTs have shown histological improvement in steatosis and 
lobular inflammation after pioglitazone treatment. In a pilot study, 
pioglitazone treatment for 48 weeks showed histological improve-
ment (steatosis, parenchymal inflammation, cellular injury, and 
Mallory bodies) in 18 non-diabetic patients with biopsy-proven 
NASH.30 In 55 patients with impaired glucose tolerance or T2DM 
(mean HbA1c 6.2%), pioglitazone treatment (45 mg daily) with a 
hypocaloric diet for 6 months resulted in improvements in insulin 
sensitivity, ALT levels, steatosis, ballooning necrosis, and inflam-
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Table 1. Molecular mechanisms of anti-diabetic drugs and their effects on nonalcoholic fatty liver disease
Anti-diabetic drugs Molecular mechanisms Weight change Effects on NAFLD
Metformin AMPK-dependent mechanisms
-  Inhibits the mitochondrial respiratory chain in the liver, leading 
to activation of AMPK, enhancing insulin sensitivity (via effects 
on fat metabolism), and lowering cAMP, and thereby reducing 
the expression of gluconeogenic enzymes
AMPK-independent mechanisms
- Inhibits fructose-1,6-bisphosphatase by AMP
Neutral (potential 
modest loss)
- Improvement of liver enzymes 
and liver fat content
Thiazolidinediones Activation of the transcription factor PPAR-γ involved in the 
transcription of genes regulating glucose and fat metabolism 
→  When activated by a ligand, PPAR-γ binds to the retinoid X 
receptor (RXR) to form a heterodimer. 
→  This binds to DNA to regulate the genetic transcription 
and translation of various proteins involved in cellular 
differentiation as well as glucose and lipid metabolism.
Gain Pioglitazone
- Improvement of liver enzymes 
and liver fat content
- Some improvement on 
histological features of NASH
Rosiglitazone and lobeglitazone
- Improvement of liver enzymes 
and liver fat content
GLP1-RAs Binding of GLP-1 receptor (pancreatic β-cells)
→  Elicits its effects via acute elevation in cAMP levels
→ Subsequent protein kinase(s) activation
→ Elevated Ca2+ and ATP
→ Stimulates insulin secretion
Loss Liraglutide
- Improvement of liver enzymes 
and liver fat content
- Potential beneficial effect on 
histological features of NASH
Exenatide and dulaglutide
- Improvement of liver enzymes 
and liver fat content
Lixisenatide and semaglutide
- Improvement of liver enzymes
DPP-4 inhibitors Competitively inhibits the enzyme DPP-4; this enzyme breaks 
down the incretin GLP-1 and GIP, which are released in 
response to a meal 
(DPP-4 is a 766 amino acid amino peptidase, and is a tetramer 
with each subunit consisting of two domains: N-terminal 
β-propeller domain & C-terminal catalytic domain).
Neutral Sitagliptin and vildagliptin
- Improvement of liver enzymes 
and liver fat content
SGLT2 inhibitors Inhibits SGLT2 action and causes reduction in renal glucose 
reabsorption 
(SGLT2 is expressed in the luminal membrane of the proximal 
tubule [mainly S1 and S2 segment]. It reabsorbs ~97% of 
filtered glucose under normoglycemic conditions).
Loss Dapagliflozin, canagliflozin, 
empagliflozin, ipragliflozin, and 
luseogliflozin
- Improvement of liver enzymes 
and liver fat content
α-glucosidase 
inhibitors
Inhibits intestinal α-glucosidase 
(Enzyme α-glucosidase is located in the brush border of the 
enterocytes of the jejunum in the small intestine, and happens 
to be a key enzyme in carbohydrate synthesis and breakdown. 
It is an exo-type carbohydrolase, which cleaves glycosidic 
bonds in complex carbohydrate to release absorbable 
monosaccharides).
Neutral No study in human
Sulfonylureas Binds to sulfonylurea receptors and causes closing of KATP 
channels on β-cell plasma membranes, influx of Ca2+, and 
stimulation of insulin release
Gain No study in human
Meglitinides Binds to sulfonylurea receptors, but at different binding sites to 
sulfonylurea causes closing of KATP channels on b-cell plasma 
membranes, influx of Ca2+, and stimulation of insulin release
Gain No study in human
NAFLD, nonalcoholic fatty liver disease; AMPK, adenosine monophosphate-activated protein kinase; cAMP, cyclic adenosine monophosphate; PPAR-γ, 
peroxisome proliferator-activated receptor-γ; NASH, nonalcoholic steatohepatitis; ATP, adenosine triphosphate; GLP1-RAs, GLP-1 receptor agonists; DPP-4, 
dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide; SGLT2, sodium-glucose cotransporter 2.
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mation of liver biopsy-confirmed NASH patients.31 Meta-analyses 
agreed with the beneficial effects of pioglitazone on lobular in-
flammation.26,32,33 However, there were conflicting results for he-
patic fibrosis. The landmark phase 3 PIVENS (Pioglitazone versus 
Vitamin E versus Placebo for the Treatment of Nondiabetic Pa-
tients with NASH) trial was conducted as a multicenter, random-
ized, placebo-controlled, double-blind clinical trial of pioglitazone 
compared to vitamin E in the treatment of NASH, by enrolling 247 
adults without diabetes who had biopsy-confirmed NASH.34 After 
a 96-week treatment period, 45 mg/day pioglitazone treatment 
was associated with reductions in serum ALT levels (P<0.001), 
hepatic steatosis (P<0.001), and lobular inflammation (P=0.004), 
but there was no improvement in fibrosis scores. On the contrary, 
another RCT was conducted in 101 patients with biopsy-proven 
NASH to investigate whether 45 mg/day pioglitazone treatment 
for 18 months could achieve the primary outcome with an im-
provement of at least two points in NAFLD activity score (NAS) 
and no worsening of fibrosis.35 Pioglitazone treatment showed 
58% achievement in the primary outcome and 51% resolution of 
NASH (P<0.001 for each). Pioglitazone treatment also was associ-
ated with improvement in individual histologic scores, including 
fibrosis score (P=0.039); reduced hepatic triglyceride content from 
19% to 7% (P<0.001); and improved adipose tissue, hepatic, and 
muscle insulin sensitivity (P<0.001 vs. placebo for all). In ad-
vanced fibrosis (stages F3–F4), meta-analysis showed that piogli-
tazone use improved fibrosis in patients with NASH and T2DM, as 
well as in patients without diabetes.36 Therefore, pioglitazone 
could be a first-line therapy for patients with NASH and T2DM. 
However, due to limited evidence, pioglitazone should be cau-
tiously used in subjects without T2DM to treat NAFLD without bi-
opsy-proven NASH.28 It is important to remember that weight 
gain, fluid retention, and bone loss are common side effects of pi-
oglitazone treatment. In this regard, the risks and benefits should 
be considered before starting therapy. 
Rosiglitazone
Rosiglitazone was once a popular TZD, but it was withdrawn 
from some markets in 2010 due to a high risk of myocardial in-
farction. In many RCTs, rosiglitazone demonstrated a biochemical 
improvement in liver enzymes and glycemic control in both dia-
betic and nondiabetic patients with NAFLD, whereas evidence of 
histological improvement was less clear.37 Although no firm asso-
ciation was found after an extensive review of all evidence by the 
United States Food and Drug Administration, rosiglitazone is no 
longer available in most countries, and its prescribing remains se-
verely restricted in the United States.
Lobeglitazone
Lobeglitazone is a novel PPAR-γ agonist developed in South Ko-
rea, and it has been used for patients with T2DM in several coun-
tries. It exhibited similar beneficial effects to other TZDs, such as 
glucose-lowering, anti-inflammatory, and antioxidant actions.38 
Regarding NAFLD, lobeglitazone treatment has limited evidence. 
In high-fat diet-induced obese mice, lobeglitazone decreased he-
patic steatosis, attenuated lipogenesis-induced oxidative liver in-
jury, and reversed hepatic lipid dysregulation.39,40 In a multicenter, 
prospective, open-label, exploratory clinical trial, 43 patients with 
NAFLD and T2DM who were treated daily with 0.5 mg lobegli-
tazone for 24 weeks experienced improved liver enzymes and 
ameliorated hepatic fat content, as assessed by vibration-con-
trolled transient elastography, with controlled attenuation param-
eters.41 Recommendations for the use of lobeglitazone are similar 
to those of pioglitazone.
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR 
AGONISTS
GLP-1 is released from intestinal epithelial L-cells in response to 
meals and secreted into circulation.42 Circulating active GLP-1 in-
duces insulin secretion in pancreatic β-cells and reduces glucagon 
secretion in pancreatic α-cells in a glucose-dependent manner. 
Since GLP-1 has a very short half-life, GLP-1 receptor agonists 
(GLP-1 RAs) were developed, and they showed a glucose-lower-
ing effect by stimulating GLP-1 receptors. In addition to the glu-
cose-lowering effect, GLP-1 RAs decrease appetite, delay gastric 
emptying, and induce weight loss. Therefore, GLP-1 RAs are an 
attractive candidate for the treatment of NAFLD, as they can re-
duce weight and enhance insulin action. However, according to 
the American Association for the Study of Liver Disease 2018 
practice guideline, it is premature to consider GLP-1 RA for the 
treatment of liver disease in patients with NAFLD or NASH, due to 
limited evidence.28 However, several meta-analyses showed that 
GLP-1 RAs have additional roles in reducing the risk of major ad-
verse CV events and CV deaths in high-risk patients with T2DM, 
especially in the Asian population.43
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Exenatide
Exenatide is a synthetic form of a hormone isolated from Gila 
monster saliva, and the first agent of GLP-1 RA to be approved 
for the treatment of T2DM. In an observational pilot study, exena-
tide showed more qualitative ultrasonographic improvements in 
patients with NAFLD and T2DM compared with gliclazide, piogli-
tazone, sitagliptin, and liraglutide, although these differences 
were not significant.44 Several RCTs have found that exenatide 
alone or combined with other anti-diabetic drugs reduced liver 
enzymes, hepatic content, hepatic triglycerides, and epicardial 
fat.45-48 However, no well-designed placebo-controlled, double-
blind study with histology-proven outcomes has evaluated the ef-
fect of exenatide on NAFLD.
Liraglutide
Liraglutide is a long-acting GLP-1 RA, and is used for T2DM 
therapy at doses of up to 1.8 mg daily. It has also been approved 
for obesity management at the dose of 3 mg daily, and has been 
included in the largest number of studies on NAFLD among the 
GLP-1 RAs. Many studies showed that liraglutide reduced liver 
enzymes.49,50 In a meta-analysis of six RCTs conducted by the “Li-
raglutide Effect and Action in Diabetes (LEAD)” program, 26 
weeks of liraglutide treatment (1.8 mg/day) improved ALT and he-
patic steatosis in 4,442 patients with T2DM.49 However, these ef-
fects were likely mediated by weight loss and glycemic control, 
since they were lost after adjustment for weight reduction and 
HbA1c. In a prospective, single-center study (LIRA-NAFLD), lira-
glutide treatment (1.2 mg/day) for 6 months decreased liver fat 
content, as measured by proton magnetic resonance spectroscopy 
(MRS), in 68 patients with uncontrolled T2DM.51 The study also 
concluded that the effect of liver fat content reduction was mainly 
driven by body weight reduction. In a randomized trial which de-
fined NAFLD as liver fat fraction >5% on magnetic resonance im-
aging (MRI), liraglutide (3 mg/day) improved hepatic steatosis and 
hepatocellular apoptosis after 26 weeks in 30 obese patients; 
however, the benefits were not sustained after discontinuation, in 
contrast to lifestyle modification.52 Histological features were 
evaluated in two trials, LEAN (Liraglutide Safety and Efficacy in 
Patients With Non-Alcoholic Steatohepatitis) and LEAN-J (Liraglu-
tide Effects in Non-Alcoholic Steatohepatitis and Non-Alcoholic 
Fatty Liver Disease With Glucose Intolerance in Japanese Pa-
tients). In the LEAN study, which was a randomized, placebo-con-
trolled phase 2 trial consisting of 52 patients with biopsy-proven 
NASH, 48 weeks of liraglutide (1.8 mg daily) was reported to re-
solve biopsy-proven NASH in nine out of 23 patients, whereas 
this was observed in only two out of 22 patients in the placebo 
group.53 In the LEAN-J study, which enrolled 19 Japanese patients 
with biopsy-proven NASH, repeated liver biopsy was performed in 
10 subjects who continued liraglutide therapy (0.9 mg/day) for 96 
weeks. Seven subjects showed improved histological inflamma-
tion, six showed reduced liver fibrosis, and eight had improved 
NAS.54 As expected, in both LEAN and LEAN-J studies, liraglutide 
was associated with significant reductions in body weight and 
BMI compared with placebo. However, their effects for NASH are 
not solely explained by the improvements in weight and metabolic 
phenotype. Liraglutide seems to be the most promising GLP-1 RA 
for NAFLD/NASH prevention and/or treatment, although large 
RCTs are needed to confirm its effects.
Lixisenatide
Similar to exenatide, lixsisenatide is based on exendin-4 with an 
addition of six lysines and deletion of a proline at the C-terminus. 
To date, there has been no RCT on lixisenatide for patients with 
NAFLD. In a meta-analysis of 12 RCTs on lixisenatide versus pla-
cebo and three RCTs with the active comparators, lixisenatide in-
creased the proportion of patients with normalization of ALT 
compared with placebo or active comparators.55
Dulaglutide
Dulaglutide is a once-weekly GLP-1 RA and has some advan-
tages, such as weekly injection, disposable and prefilled devices, 
as well as safety profiles similar to those of other GLP-1 RAs. The 
effect of dulaglutide on NAFLD is not well-known, as only a few 
studies have been conducted. In a post hoc  analysis of AWARD 
(Assessment of Weekly Administration of LY2189265 [dulaglutide] 
in Diabetes) trials, dulaglutide (1.5 mg once weekly) improved liv-
er enzymes compared with placebo in a pattern consistent with 
liver fat reduction.56 In a Japanese retrospective study, dulaglutide 
(0.75 mg once weekly) significantly improved liver enzymes and 
liver stiffness, as measured by transient elastography after 12 
weeks of therapy in T2DM patients with biopsy-proven NASH.57 
Semaglutide
Semaglutide is a human GLP-1 RA and has two forms, a once-
weekly injectable agent and a once-daily oral agent. Currently, 
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there is limited evidence regarding the effect of semaglutide on 
NAFLD. In a sub-analysis of the 104-week CV outcomes trial of 
T2DM (semaglutide 0.5 or 1.0 mg/week) and a 52-week weight 
management trial (semaglutide 0.05–0.4 mg/day), semaglutide 
significantly reduced ALT in subjects with T2DM.58 To investigate 
the safety and efficacy of semaglutide (once-daily subcutaneous 
injection) on NASH (stage 1–3 fibrosis), a phase 2, randomized, 
double-blind, placebo-controlled trial (SEMA-NASH study, 
NCT02970942) was initiated, the final results of which are cur-
rently pending. However, there is no existing data regarding the 
effects of an oral form of semaglutide on NAFLD.
Tirzepatide
Tirzepatide is a novel unimolecular, multi-functional peptide 
that combines GLP-1 and glucose-dependent insulinotropic poly-
peptide (GIP) receptor agonist activities. GIP is an incretin secret-
ed from K cells in the upper small intestine in response to food. 
Unlike GLP-1, GIP is both glucagonotropic and insulinotropic in a 
glucose-dependent manner, dose-dependently stimulating gluca-
gon secretion under hypoglycemic conditions and insulin under 
hyperglycemic conditions.59 The number of studies conducted to 
demonstrate the effect of tirzepatide on NAFLD is very limited. 
Patients with T2DM received either once weekly tirzepatide (1, 5, 
10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks. In 
post hoc analyses, significant (P<0.05) reductions from baseline 
in ALT (all groups), aspartate aminotransferase (AST) (all groups 
except tirzepatide 10 mg), keratin-18 (tirzepatide 5, 10, 15 mg), 
and procollagen III (tirzepatide 15 mg) were observed at 26 
weeks.60 Although one study cannot provide sufficient evidence 
of efficacy for tirzepatide in subjects with NASH, weight reduction 
along with changes in NASH biomarker suggest the need for fur-
ther trials of tirzepatide in subjects with NASH.
DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS
DPP-4 inhibitors demonstrate a glucose-lowering effect by in-
creasing the incretin effect through the delay of quick inactivation 
of GLP-1 in plasma. Several studies found that serum DPP-4 level 
was elevated in NASH patients, and also correlated with hepatic 
steatosis, fibrosis, and hepatocyte apoptosis.61,62 These findings 
support the notion that DPP-4 inhibitors may improve the histo-
logical features of NAFLD/NASH; however, there has been only a 
few studies demonstrating the significant efficacy of DPP-4 inhibi-
tors in patients with NAFLD. DPP-4 inhibitors are not yet believed 
to have a beneficial effect on NAFLD.
Sitagliptin
As a first-in-class DPP-4 inhibitor, sitagliptin has been most 
widely studied to evaluate its efficacy on NAFLD/NASH. However, 
sitagliptin has shown conflicting evidence regarding its effects on 
NAFLD. Sitagliptin treatment (50 mg/day) for 4 months improved 
liver enzymes in patients with NAFLD (n=30) diagnosed by ultra-
sound.63 In an observational pilot study of 15 T2DM patients with 
biopsy-proven NASH, sitagliptin treatment (100 mg/day) for 
1 year ameliorated liver enzymes, hepatocyte ballooning, and 
NASH scores.64 In a prospective, 24-week, single-center, open-la-
bel comparative study that enrolled 20 Japanese patients with 
T2DM and NAFLD, sitagliptin significantly reduced intrahepatic 
lipid content, as assessed by 1) H-MRS, and total body fat mass 
after 24 weeks.65 On the other hand, in 44 patients with T2DM 
and biopsy-proven NAFLD, sitagliptin treatment (50 mg/day) for 
12 months did not reduce liver enzymes, although HbA1c was re-
duced by 0.7%.66 In a RCT that enrolled 50 NAFLD patients, liver 
enzymes and magnetic resonance elastography-derived liver stiff-
ness were not improved by 24 weeks of sitagliptin treatment (100 
mg/day).67 Moreover, in many existing studies, sitagliptin treat-
ment failed to produce any reduction in liver fat content and liver 
enzymes.68,69 Based on previous clinical trials, sitagliptin is not yet 
believed to have a beneficial effect on NAFLD.
Vildagliptin
A few trials have demonstrated that vildagliptin has an effect 
on NAFLD. In 44 patients with T2DM and hepatic steatosis, vilda-
gliptin treatment (50 mg twice daily) for 6 months decreased liver 
enzymes and intrahepatic triglyceride content, as assessed by 
MRI.70 In a RCT conducted in Pakistan, vildagliptin (50 mg twice 
daily) for 12 weeks improved liver enzymes and steatosis grading, 
as assessed by ultrasound.71
Other DPP-4 inhibitors
Not many studies have been conducted to evaluate the efficacy 
of other DPP-4 inhibitors, including gemigliptin, alogliptin, teneli-
gliptin, saxagliptin, anagliptin, and linagliptin, on NAFLD. In an 
animal model, many DPP-4 inhibitors, including gemigliptin, alo-
gliptin, teneligliptin, and linagliptin, were able to alleviate hepatic 
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steatosis and hepatic lipogenesis.72-75 In human clinical trials, 12 
months of alogliptin treatment (25 mg/day) in NAFLD patients 
with T2DM yielded a decrease in NAFLD progression.76 With saxa-
gliptin, liver enzymes and hepatic steatosis were improved after 
treatment for 24 weeks in 95 patients with NAFLD and T2DM.77
SODIUM-GLUCOSE COTRANSPORTER 2 
(SGLT2) INHIBITORS
SGLT2 is responsible for a majority of the glucose reabsorption 
that occurs in proximal renal tubules. SGLT2 inhibitors are a novel 
class of anti-diabetic drugs that improve hyperglycemia by inhibit-
ing urinary glucose reabsorption from the kidney.78 In addition to 
a glucose-lowering effect, SGLT2 inhibitors exert several cardiore-
nal and metabolic benefits, including weight loss; therefore, they 
are thought to be promising therapeutic agents for patients with 
NAFLD.79 Although beneficial effects continue to be reported, 
SGLT2 inhibitors are not yet generally recommended for the treat-
ment of NAFLD.
Dapagliflozin
Many small-scale studies have shown that dapagliflozin treat-
ment improved liver enzymes, liver fat content, or liver stiffness in 
patients with NAFLD.80,81 In a single-arm, nonrandomized, open-
label study, dapagliflozin treatment (5 mg/day) for 24 weeks re-
duced liver enzymes and metabolic parameters in 11 patients with 
biopsy-proven NASH.82 The Effects of Omega-3 Carboxylic Acids 
and Dapagliflozin on Liver Fat Content in Diabetic Patients (EF-
FECT-II) study found that dapagliflozin (10 mg/day) combined with 
omega-3 carboxylic acids reduced liver fat content, as assessed by 
MRI-derived proton density fat fraction (MRI-PDFF), and dapa-
gliflozin monotherapy reduced all measured hepatocyte injury 
markers in patients with T2DM and NAFLD.83 In a randomized, 
active-controlled, open-label trial, dapagliflozin treatment (5 
mg/day) for 24 weeks improved liver enzymes, steatosis, and fi-
brosis, as measured by transient elastography (FibroScan), in 57 
patients with T2DM and NAFLD, as defined by ultrasound.84 Fur-
thermore, the Dapagliflozin Efficacy and Action in NASH (DEAN) 
study (NCT03723252) is still ongoing, with the objective to assess 
the efficacy and safety of dapagliflozin for improving biopsy-prov-
en NASH and metabolic risk factors. This study is a phase 3, mul-
ticenter, randomized, double-blind, placebo-controlled trial, and 
will enroll 100 participants until November 2021.
Canagliflozin
Several studies have evaluated the efficacy of canagliflozin on 
NAFLD.85-88 A meta-analysis of 11 trials with a total of 6,745 
T2DM patients reported that canagliflozin significantly decreased 
liver enzymes.85 In a RCT, canagliflozin (300 mg/day) for 24 weeks 
reduced liver enzymes and intrahepatic triglyceride content, as 
measured by proton-MRS, in 37 patients with T2DM and NAFLD.86 
Likewise, in a small (n=20), prospective, non-randomized, open-
label, single-arm study, canagliflozin (100 mg daily) treatment for 
12 months significantly reduced hepatic fat fraction, as measured 
by MRI, in patients with T2DM and NAFLD.87 In nine patients with 
T2DM and biopsy-proven NASH, canagliflozin treatment (100 
mg/day) for 24 weeks improved the histological features of NASH, 
including steatosis, lobular inflammation, ballooning, and fibrosis 
stage.88 
Empagliflozin
Only a few studies have evaluated the efficacy of empagliflozin 
on NAFLD. In the Empagliflozin Cardiovascular Outcome Event 
Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), 
empagliflozin reduced liver enzymes (ALT>AST) in patients with 
T2DM.89 A single-center, retrospective, observational study found 
that empagliflozin (5 mg/day) for 6 months significantly improved 
liver enzymes in 46 patients with T2DM.90 The Effect of Empa-
gliflozin on Liver Fat Content in Patients With Type 2 Diabetes (E-
LIFT) trial, an investigator-initiated, prospective, open-label, ran-
domized clinical study involving 50 patients with T2DM and 
NAFLD, showed that empagliflozin (10 mg daily) for 20 weeks 
significantly reduced liver enzymes and liver fat, as measured by 
MRI-PDFF.91
Ipragliflozin
Ipragliflozin is used in several countries, including South Korea 
and Japan. In 43 patients with T2DM and NAFLD, ipragliflozin 
treatment for 24 weeks (50 mg daily) reduced liver enzymes.92 
Despite the small number of studies, ipragliflozin showed similar 
beneficial effects to pioglitazone on NAFLD. The open-label, ran-
domized, active-controlled trial compared the efficacy of ipra-
gliflozin (50 mg daily) versus pioglitazone (15–30 mg daily) in 66 
patients with T2DM and NAFLD. At week 24, ipragliflozin exerted 
equally beneficial effects on NAFLD compared with pioglitazone.93 
Furthermore, ipragliflozin (50 mg daily) treatment for 24 weeks 
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significantly ameliorated liver steatosis and reduced excessive fat 
in 44 euglycemic patients with T2DM and NAFLD who were tak-
ing metformin and pioglitazone at baseline.94
Other SGLT2 inhibitors
Several pre-clinical studies conducted with animal experimental 
models have shown that luseogliflozin and remogliflozin could be 
associated with improvement in hepatic steatosis.95,96 In 32 pa-
tients with T2DM and NAFLD diagnosed by abdominal computed 
tomography or ultrasound, luseogliflozin treatment (2.5 mg daily) 
for 6 months reduced liver fat deposition compared to metfor-
min.97 A prospective, single-arm trial (LEAD trial) showed that 
luseogliflozin treatment (2.5 mg daily) for 24 weeks reduced he-
patic fat content, as evaluated by MRI, in patients with T2DM and 
NAFLD.98
α–GLUCOSIDASE INHIBITORS
α-glucosidase inhibitors, including acarbose, miglitol, and vogli-
bose, are oral glucose-lowering agents that specifically inhibit 
α-glucosidases in the brush border of the small intestine to pre-
vent digestion of carbohydrates, such as starch and sugar. To 
date, only a limited number of studies have investigated the effect 
of α-glucosidase inhibitors on NAFLD. In a mouse model of 
NAFLD, combination therapy with ezetimibe and acarbose for 24 
weeks improved the histopathological findings.99 Administration 
of miglitol (150 mg/day) for 12 months in 17 T2DM patients with 
histologically-confirmed NASH showed significantly decreased 
BMI and serum ALT.100 Post-treatment liver biopsy of 11 patients 
revealed significant improvements in steatosis, lobular inflamma-
tion, portal inflammation scores, and NAFLD activity scores (from 
5.5±1.5 to 3.9±1.4, P=0.012). However, fibrosis and hepatocyte 
ballooning scores remained unchanged.
SULFONYLUREAS AND MEGLITINIDES
Insulin resistance with hyperinsulinemia might be deleterious to 
the liver and associated with high intrahepatic triglyceride con-
tent.101 Sulfonylureas and meglitinides are insulin secretagogues 
that lower glucose level by enhancing insulin secretion from pan-
creatic β-cells. Metformin and pioglitazone may be safely used in 
patients with NAFLD, whereas sulfonylureas and insulin itself 
have been associated with NAFLD progression and adverse out-
comes.102 This class of drugs has rarely been studied regarding its 
impact on NAFLD.
DRUGS UNDER INVESTIGATION
Various types of promising therapeutic targets for T2DM are 
under investigation. Protein tyrosine phosphatase 1B inhibitor, 
free fatty acid receptors 1, aldose reductase, glycogen phosphory-
lase, fructose-1, 6-bisphosphatase, glucagon receptor antagonist, 
and phosphoenolpyruvate carboxykinase are currently being as-
sessed.103 Among them, drugs that show weight reduction can be 
effective in the treatment of NAFLD. Further studies are warrant-
ed to evaluate the efficacy of novel anti-diabetic drugs for NAFLD.
CONCLUSIONS
To this day, the only approved treatment option for NAFLD is 
weight reduction, although much progress has been made in the 
understanding, diagnosis, and treatment of NAFLD over past de-
cades. Since T2DM and NAFLD have a partly shared pathophysiol-
ogy that includes insulin resistance even genetically,104-106 anti-dia-
betic drugs are a good candidate for the treatment of NAFLD. 
Most anti-diabetic drugs showed an improvement in liver en-
zymes, but there is limited evidence of any beneficial effect on 
histological outcomes. Among anti-diabetic drugs, pioglitazone 
has the strongest evidence for a role in NAFLD treatment, and it 
has shown improvement in liver histology for patients with biop-
sy-proven NASH. Liraglutide has also shown promising evidence, 
although it is premature to consider a GLP-1 RA for the treatment 
of liver disease in patients with NAFLD. Further well-designed 
RCTs should be conducted to determine the role of these anti-dia-
betic drugs in NAFLD treatment.
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